SOM Biotech

SOM Biotech is a Spanish biotech leveraging its proprietary AI platform, SOMaiPRO®, to accelerate drug discovery for rare CNS conditions with high unmet need. The platform has demonstrated strong clinical predictivity, with two identified compounds achieving positive Phase 2a proof-of-concept results. The company's lead program, SOM3355 for Huntington's disease, is poised to enter Phase 3, positioning SOM Biotech as a late-stage clinical development entity. Its strategy combines AI-driven discovery with deep clinical expertise to build a targeted pipeline in valuable, underserved neurological and psychiatric markets.

SOMaiPRO®: A proprietary AI-based drug discovery platform that matches molecular fields to discover structure-unrelated analogs from a library of molecules tested in humans. It is designed for high clinical predictivity, especially in rare diseases with limited biological data.

SOM Biotech competes in the rare CNS space with both traditional biopharma companies and other AI-driven drug discovery firms. Its key differentiator is the clinical validation of its AI platform (Phase 2a successes) and its late-stage clinical asset, which is rare among AI-native biotechs. However, larger companies with greater resources are also active in indications like Huntington's and Tardive Dyskinesia.